Human enteroviruses (HEVs) can cause severe infections, especially in patients with a deficient humoral immune response, such as X-linked agammaglobulinemia. In this patient group, chronic enteroviral meningitis (CEMA) is feared because of extensive morbidity and high fatality rate. Treatment options consist of intravenous immunoglobulin (IVIG), with various outcomes. Pleconaril is an antiviral agent with in vitro activity against HEVs that has been used in the treatment of HEV infections.
Methods
The efficacy of pleconaril and IVIG against HEV isolated from the patients was assessed in vitro in two patients with CEMA.
Results
Echovirus 11 was found in the cerebrospinal fluid (CSF) of case 1. Treatment with high-dose IVIG and pleconaril did not provide any clinical improvement and HEV PCR in CSF remained positive. Case 2 (echovirus 13 positive in CSF) was also treated with IVIG and pleconaril. The patient recovered completely and HEV PCR in CSF became negative. Recent IVIG batches contained low titres of neutralizing antibodies against the patient strains. Echovirus 11 (case 1) was resistant to pleconaril in vitro, whereas echovirus 13 (case 2) was susceptible, in accordance with virological response after treatment and subsequent clinical results.
Conclusions
This is the first report that evaluates efficacy of antiviral treatment in CEMA patients in relation to in vitro susceptibility of clinical virus isolates. Since pleconaril is no longer available for compassionate use we strongly propagate that new drugs should be developed against these potential life threatening HEV infections.
References
1.
RotbartH.A.Enteroviral infections of the central nervous system. Clin Infect Dis1995; 20: 971–981.
2.
RudgeP., WebsterA.D., ReveszT.Encephalomyelitis in primary hypogammaglobulinaemia. Brain1996; 119: 1–15.
ConleyM.E., BroidesA., Hernandez-TrujilloV.Genetic analysis of patients with defects in early B-cell development. Immunol Rev2005; 203: 216–234.
5.
WinkelsteinJ.A., MarinoM.C., LedermanH.M.X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore)2006; 85: 193–202.
6.
BasileN., DanielianS., OleastroM.Clinical and molecular analysis of 49 patients with X-linked agammaglobulinemia from a single center in Argentina. J Clin Immunol2009; 29: 123–129.
7.
PlebaniA., SoresinaA., RondelliR.Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol2002; 104: 221–230.
8.
MoinM., AghamohammadiA., FarhoudiA.X-linked agammaglobulinemia: a survey of 33 Iranian patients. Immunol Invest2004; 33: 81–93.
9.
HallidayE., WinkelsteinJ., WebsterA.D.Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Infect2003; 46: 1–8.
10.
MisbahS.A., SpickettG.P., RybaP.C.Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol1992; 12: 266–270.
11.
CrennanJ.M., Van ScoyR.E., McKennaC.H., SmithT.F.Echovirus polymyositis in patients with hypogammaglobulinemia. Failure of high-dose intravenous gammaglobulin therapy and review of the literature. Am J Med1986; 81: 35–42.
12.
RotbartH.A., WebsterA.D.Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis2001; 32: 228–235.
13.
PevearD.C., TullT.M., SeipelM.E., GroarkeJ.M.Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother1999; 43: 2109–2115.
14.
DesmondR.A., AccorttN.A., TalleyL., VillanoS.A., SoongS.J., WhitleyR.J.Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother2006; 50: 2409–2414.
15.
AbzugM.J., CloudG., BradleyJ.Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J2003; 22: 335–340.
16.
BenschopK., MolenkampR., van der HamA., WolthersK., BeldM.Rapid detection of human parechoviruses in clinical samples by real-time PCR. J Clin Virol2008; 41: 69–74.
17.
BenschopK., MinnaarR., KoenG.Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples; polymerase chain reaction and direct molecular typing, culture characteristics, and serotyping. Diagn Microbiol Infect Dis2010; 68: 166–173.
18.
KapsenbergJ.G.Picornaviridae; the enteroviruses (polioviruses, coxsackieviruses, echoviruses). In BalowsA., HauslerW.J., LennetteE. (Editors). Laboratory diagnosis of infectious diseases. Principles and Practice.New York: Springer-Verlag1988; pp. 692–722.
19.
McWilliam LeitchE.C., HarvalaH., RobertsonI., UbillosI., TempletonK., SimmondsP.Direct identification of human enterovirus serotypes in cerebrospinal fluid by amplification and sequencing of the VP1 region. J Clin Virol2009; 44: 119–124.
20.
NixW.A., ObersteM.S., PallanschM.A.Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol2006; 44: 2698–2704.
21.
KaiserL., CrumpC.E., HaydenF.G.In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res2000; 47: 215–220.
22.
ReedL., MuenchH.A simple method of estimating fifty per cent endpoints. Am J Hyg1938; 27: 493–497.
23.
WebsterA.D.Pleconaril – an advance in the treatment of enteroviral infection in immuno-compromised patients. J Clin Virol2005; 32: 1–6.
24.
ArchimbaudC., BaillyJ.L., ChambonM., TournilhacO., TravadeP., Peigue-LafeuilleH.Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000. J Clin Microbiol2003; 41: 4605–4610.
25.
QuartierP., ForayS., CasanovaJ.L., Hau-RainsardI., BlancheS., FischerA.Enteroviral meningoencephalitis in X-linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain reaction. Pediatr Infect Dis J2000; 19: 1106–1108.
26.
Nowak-WegrzynA., PhipatanakulW., WinkelsteinJ.A., FormanM.S., LedermanH.M.Successful treatment of enterovirus infection with the use of pleconaril in 2 infants with severe combined immunodeficiency. Clin Infect Dis2001; 32: e13–e14.
27.
TormeyV.J., BuscombeJ.R., JohnsonM.A., ThomsonA.P., WebsterA.D.SPECT scans for monitoring response to pleconaril therapy in chronic enteroviral meningoencephalitis. J Infect2003; 46: 138–140.
28.
SchmuggeM., LauenerR., BossartW., SegerR.A., GungorT.Chronic enteroviral meningo-encephalitis in X-linked agammaglobulinemia: favourable response to anti-enteroviral treatment. Eur J Pediatr1999; 158: 1010–1011.
29.
StarlinR., ReedN., LeemanB., BlackJ., TrulockE., MundyL.M.Acute flaccid paralysis syndrome associated with echovirus 19, managed with pleconaril and intravenous immunoglobulin. Clin Infect Dis2001; 33: 730–732.
30.
KatsibardiK., MoschoviM.A., TheodoridouM.Enterovirus-associated hemophagocytic syndrome in children with malignancy: report of three cases and review of the literature. Eur J Pediatr2008; 167: 97–102.
31.
CreeB.C., BernardiniG.L., HaysA.P., LoweG.A fatal case of coxsackievirus B4 meningoencephalitis. Arch Neurol2003; 60: 107–112.
32.
SchmidtkeM., HammerschmidtE., SchulerS.Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother2005; 56: 648–656.
33.
McWilliam LeitchE.C., CabrerizoM., CardosaJ.Evolutionary dynamics and temporal/geographical correlates of recombination in the human enterovirus echovirus types 9, 11, and 30. J Virol2010; 84: 9292–9300.
34.
Savolainen-KopraC., Al-HelloH., PaananenA.Molecular epidemiology and dual serotype specificity detection of echovirus 11 strains in Finland. Virus Res2009; 139: 32–38.
35.
AbzugM.J., KeyserlingH.L., LeeM.L., LevinM.J., RotbartH.A.Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis1995; 20: 1201–1206.
36.
GalamaJ.M., VogelsM.T., JansenG.H., GielenM., HeessenF.W.Antibodies against enteroviruses in intravenous Ig preparations: great variation in titres and poor correlation with the incidence of circulating serotypes. J Med Virol1997; 53: 273–276.
37.
DiedrichS., SchreierE.Aseptic meningitis in Germany associated with echovirus type 13. BMC Infect Dis2001; 1: 14.
38.
MullinsJ.A., KhetsurianiN., NixW.A.Emergence of echovirus type 13 as a prominent enterovirus. Clin Infect Dis2004; 38: 70–77.
39.
De PalmaA.M., VliegenI., DeC.E., NeytsJ.Selective inhibitors of picornavirus replication. Med Res Rev2008; 28: 823–884.
